Icon (NASDAQ:ICLR) Issues FY 2025 Earnings Guidance

Icon (NASDAQ:ICLR - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 13.000-14.000 for the period, compared to the consensus earnings per share estimate of 13.264. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

Icon Trading Down 4.1%

Icon stock traded down $8.00 during trading hours on Friday, hitting $187.01. The stock had a trading volume of 1,598,445 shares, compared to its average volume of 1,328,831. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.36. The stock has a market cap of $15.10 billion, a price-to-earnings ratio of 19.24, a P/E/G ratio of 2.53 and a beta of 1.17. Icon has a one year low of $125.10 and a one year high of $338.67. The business's 50 day simple moving average is $143.46 and its 200-day simple moving average is $164.43.

Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.94% and a net margin of 9.82%. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period last year, the company earned $3.75 earnings per share. The firm's revenue was down 4.8% compared to the same quarter last year. On average, equities analysts predict that Icon will post 13.38 EPS for the current fiscal year.

Analyst Ratings Changes

ICLR has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their target price on Icon from $180.00 to $160.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group raised their target price on Icon from $170.00 to $240.00 and gave the stock a "buy" rating in a research note on Friday. Robert W. Baird raised Icon from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $150.00 to $224.00 in a research note on Thursday. JPMorgan Chase & Co. cut shares of Icon from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $265.00 to $150.00 in a research report on Tuesday, April 29th. Finally, Truist Financial increased their price objective on shares of Icon from $187.00 to $234.00 and gave the stock a "buy" rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Icon currently has an average rating of "Moderate Buy" and a consensus target price of $219.54.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.